치료 저항성 우울증 치료 시장 - 예측(2026-2031년)

The Treatment-Resistant Depression Treatment Market is projected to expand at a 5.87% CAGR, attaining USD 5.342 billion in 2031 from USD 3.794 billion in 2025.

The treatment-resistant depression (TRD) treatment market is projected to expand at a steady pace throughout the forecast period, driven by the persistent failure of first- and second-line antidepressant therapies in a substantial subset of patients with major depressive disorder (MDD). TRD, typically defined as non-response to at least two adequate trials of antidepressant monotherapy, affects approximately 30% of the 280 million adults worldwide with depression and is associated with markedly elevated suicide risk, functional impairment, and healthcare utilization.

Core growth drivers remain the escalating global burden of MDD and its treatment-refractory forms, compounded by heightened suicide rates directly linked to depressive illness. Depression continues to rank among the leading causes of disability, with suicide claiming approximately 700,000 lives annually according to WHO data. The strong correlation between untreated or inadequately managed depression and completed suicide underscores the clinical urgency for effective TRD interventions.

Increased public and professional awareness, supported by sustained international and national campaigns, is translating into higher help-seeking behavior and earlier identification of non-responders. Ongoing WHO-led initiatives, the legacy of the European Mental Health Action Plan, World Mental Health Day mobilization, and national programs continue to normalize mental health care and reduce stigma, funneling greater patient volumes into specialist settings where TRD is diagnosed and managed.

Therapeutic innovation is centered on rapid-acting and mechanistically novel agents that address the limitations of conventional monoaminergic antidepressants. Esketamine (S-ketamine) nasal spray remains the only FDA-approved therapy specifically indicated for TRD and continues to drive category expansion through real-world evidence of rapid and sustained symptom reduction. Augmentation strategies employing second-generation antipsychotics and lithium retain the strongest evidence base among traditional approaches, while glutamate-modulating candidates continue to advance through clinical pipelines.

North America maintains clear market dominance, supported by the highest reported TRD prevalence, advanced research infrastructure, rapid regulatory review pathways, and favorable reimbursement for both pharmacotherapy and interventional modalities (e.g., TMS, ECT, and esketamine administration under REMS). The region benefits from concentrated pharmaceutical investment and a mature network of academic mood-disorder centers capable of delivering complex, multistep treatment algorithms.

Key industry participants are pursuing differentiated mechanisms of action to capture share in this high-unmet-need segment:

• Pfizer Inc continues to support PRISTIQ (desvenlafaxine) for MDD while maintaining broader neuroscience capabilities that indirectly bolster TRD management.
• Novartis AG is advancing MIJ-821, a direct NMDA receptor antagonist, currently in phase II evaluation for TRD, representing a next-generation effort to replicate and potentially improve upon the esketamine proof-of-concept.
• Hikma Pharmaceuticals Plc contributes through its expanding portfolio of generic and specialty injectables that support acute stabilization and augmentation protocols.

The competitive landscape remains dynamic, with established players focusing on life-cycle management of approved assets and emerging biotechnology firms pursuing novel glutamatergic, opioid-modulating, and neuroplasticity-enhancing mechanisms. Increasing venture funding directed toward mental health platforms continues to fuel early-stage research, although post-2023 capital deployment patterns reflect a more selective investment climate.

Overall, the TRD treatment sector is positioned for sustained growth, underpinned by immutable epidemiological trends, progressive destigmatization, and a broadening armamentarium led by esketamine and next-wave NMDA-targeted therapies. North America will continue to lead in market size and innovation velocity, while regulatory approvals and guideline inclusion of rapid-acting agents progressively reshape standard-of-care algorithms for the estimated one-third of MDD patients who fail conventional antidepressant treatment.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Global Treatment-Resistant Depression Treatment Market is analyzed into the following segments:

• By Type
• Mild
• Severe
• By Drug Type
• NMDA
• Antidepressants
• Antipsychotics
• Others
• By Route of Administration
• Oral
• Parenteral
• Others
• By Distribution Channel
• Online
• Offline
• Hospital Pharmacies
• Drug Stores
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations
• 3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY TYPE

• 5.1. Introduction
• 5.2. Mild
• 5.3. Severe

6. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY DRUG TYPE

• 6.1. Introduction
• 6.2. NMDA
• 6.3. Antidepressants
• 6.4. Antipsychotics
• 6.5. Others

7. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY ROUTE OF ADMINISTRATION

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parental
• 7.4. Others

8. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY DISTRIBUTION CHANNEL

• 8.1. Introduction
• 8.2. Online
• 8.3. Offline
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Drug Stores

9. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. USA
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. South America
  • 9.3.1. Brazil
  • 9.3.2. Argentina
  • 9.3.3. Others
• 9.4. Europe
  • 9.4.1. Germany
  • 9.4.2. France
  • 9.4.3. United Kingdom
  • 9.4.4. Spain
  • 9.4.5. Others
• 9.5. Middle East and Africa
  • 9.5.1. Saudi Arabia
  • 9.5.2. UAE
  • 9.5.3. Israel
  • 9.5.4. Others
• 9.6. Asia Pacific
  • 9.6.1. China
  • 9.6.2. India
  • 9.6.3. Japan
  • 9.6.4. South Korea
  • 9.6.5. Indonesia
  • 9.6.6. Thailand
  • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Pfizer Inc
• 11.2. Novartis AG
• 11.3. Johnson & Johnson
• 11.4. AbbVie Inc
• 11.5. Otsuka Pharmaceutical Co., Ltd
• 11.6. Eli Lilly and Company
• 11.7. AstraZeneca Plc
• 11.8. Sage Therapeutics

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key Benefits for the Stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations